DifGen Pharmaceuticals Announces First Major European Milestone with Successful Completion of Decentralised Procedure for Tafamidis 61 mg Capsules

The Quick Take
Significant regulatory achievement marks an important step in DifGen's European expansion and strengthens its foundation for strategic partnerships MIRAMAR, Fla., Oct. 27, 2026 /PRNewswire/ -- DifGen Pharmaceuticals LLC ("DifGen"), a U.S.-based pharmaceutical company focused on the...
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.


